VANCOUVER, Canada I September 5, 2012 I biOasis Technologies Inc. (BTI.V) announced today that a key animal study in its BT2111 oncology program, showed that BT2111, biOasis’ conjugate of trastuzumab (Herceptin(R)) designed to treat brain metatastsis of HER2+ breast cancer, arrests the growth tumors in a xenograft model of human breast carcinoma. The human tumor xenograft model is accepted industry-wide as a gold standard for assessing the performance of new and emerging drugs to treat cancer. The model is described here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2562196/.
Briefly, a highly aggressive human breast carcinoma was transplanted subcutaneoulsy into recipient animals. The animals were treated twice per week for 6 weeks with either BT2111, Herceptin(R) or a placebo. Each week the tumor volumes were measured. In the placebo control animals, the tumors increased in size by 400% over baseline. In both the BT2111 and Herceptin(R) treated groups, the tumor growth was completely halted. Further, both Herceptin(R) and BT2111 were well tolerated with no apparent signs of toxicity.
"Over the past year the Herceptin(R)-BT2111 conjugate program has delivered some exceptional results for biOasis," says Rob Hutchison, CEO. "The next vital step for us in our BT2111 program, was to assess its performance in this cancer xenograft study. In this study, we were able to compare directly the Herceptin(R)-BT2111 conjugate to Herceptin(R) alone. The results demonstate that the Herceptin(R)-BT2111 conjugate is as active as, and at several timepoints exceeded Herceptin(R), in stopping tumor growth. Herceptin(R) is a potentailly life-saving treatment that reduces the recurrance of HER2+ breast cancer among women undergoing chemotherapy. Unfortunately, this drug is excluded from the brain and is thus ineffective for treating women with brain metastasis of HER2+ breast cancer. We have announed previously that a large percentage of intravenously administered Herceptin(R)-BT2111 conjugate enters the brains of experimental animals. Our next step is to demonstrate in collaboration with Texas Tech University that our Herceptin(R)-BT2111 conjugate is efficacious in stopping the growth of brain metastases of breast cancer." For further information on this, click this video link "xenograft" on the biOasis home page – http://www.bioasis.ca/
ABOUT BT2111 – BT2111 is a conjugate between biOasis’ Transcend brain delivery vector and trastuzumab (trade name of Herceptin(R)), a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier, biOasis is researching the potential of BT2111 for treatment of HER2+ metastatic breast cancer in the brain.
Herceptin(R) is a registered trademark of Roche/Genentech.
ABOUT BIOASIS
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more information about the Company please visit www.bioasis.ca.
SOURCE: biOasis Technologies
Post Views: 63
VANCOUVER, Canada I September 5, 2012 I biOasis Technologies Inc. (BTI.V) announced today that a key animal study in its BT2111 oncology program, showed that BT2111, biOasis’ conjugate of trastuzumab (Herceptin(R)) designed to treat brain metatastsis of HER2+ breast cancer, arrests the growth tumors in a xenograft model of human breast carcinoma. The human tumor xenograft model is accepted industry-wide as a gold standard for assessing the performance of new and emerging drugs to treat cancer. The model is described here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2562196/.
Briefly, a highly aggressive human breast carcinoma was transplanted subcutaneoulsy into recipient animals. The animals were treated twice per week for 6 weeks with either BT2111, Herceptin(R) or a placebo. Each week the tumor volumes were measured. In the placebo control animals, the tumors increased in size by 400% over baseline. In both the BT2111 and Herceptin(R) treated groups, the tumor growth was completely halted. Further, both Herceptin(R) and BT2111 were well tolerated with no apparent signs of toxicity.
"Over the past year the Herceptin(R)-BT2111 conjugate program has delivered some exceptional results for biOasis," says Rob Hutchison, CEO. "The next vital step for us in our BT2111 program, was to assess its performance in this cancer xenograft study. In this study, we were able to compare directly the Herceptin(R)-BT2111 conjugate to Herceptin(R) alone. The results demonstate that the Herceptin(R)-BT2111 conjugate is as active as, and at several timepoints exceeded Herceptin(R), in stopping tumor growth. Herceptin(R) is a potentailly life-saving treatment that reduces the recurrance of HER2+ breast cancer among women undergoing chemotherapy. Unfortunately, this drug is excluded from the brain and is thus ineffective for treating women with brain metastasis of HER2+ breast cancer. We have announed previously that a large percentage of intravenously administered Herceptin(R)-BT2111 conjugate enters the brains of experimental animals. Our next step is to demonstrate in collaboration with Texas Tech University that our Herceptin(R)-BT2111 conjugate is efficacious in stopping the growth of brain metastases of breast cancer." For further information on this, click this video link "xenograft" on the biOasis home page – http://www.bioasis.ca/
ABOUT BT2111 – BT2111 is a conjugate between biOasis’ Transcend brain delivery vector and trastuzumab (trade name of Herceptin(R)), a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier, biOasis is researching the potential of BT2111 for treatment of HER2+ metastatic breast cancer in the brain.
Herceptin(R) is a registered trademark of Roche/Genentech.
ABOUT BIOASIS
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more information about the Company please visit www.bioasis.ca.
SOURCE: biOasis Technologies
Post Views: 63
